Mayo Clinic | Strategic Alliance Partners

September 10, 2024

About 8 to 10 million Americans over 40 have excess white blood cells, which may increase their risk of melanoma.

September 10, 2024

Grzegorz S. Nowakowski, MD, discusses toxicity monitoring strategies for epcoritamab treatment in relapsed/refractory follicular lymphoma.

September 09, 2024

Grzegorz S. Nowakowski, MD, discusses how epcoritamab may fill an unmet need for patients with relapsed/refractory follicular lymphoma.

September 09, 2024

Radhika Bansal, MBBS, discusses data showing the safety and feasibility of outpatient CAR T-cell infusion in relapsed/refractory non-Hodgkin lymphoma.

September 05, 2024

The panel concludes by offering final thoughts and insights on recent advancements from EHA 2024.

September 04, 2024

Grzegorz S. Nowakowski, MD, discusses results from the EPCORE NHL-1 trial of third-line epcoritamab in relapsed/refractory follicular lymphoma.

August 29, 2024

Key opinion leaders provide concise insights on the potential of bispecific antibodies as emerging novel therapeutic agents for relapsed/refractory chronic lymphocytic leukemia.

August 29, 2024

Nicole Lamanna, MD, offers expert insights on the emerging data for second-generation BCL2 inhibitors in relapsed/refractory chronic lymphocytic leukemia, highlighting recent advancements in the field.

August 22, 2024

Key opinion leaders analyze the potential significance of preliminary data on BGB-16673, a BTK inhibitor degrader, in anticipation of its presentation at EHA 2024.

August 22, 2024

The panel explores potential applications and impact of BTK inhibitor degraders as an emerging class of novel agents for treating relapsed/refractory chronic lymphocytic leukemia.

August 15, 2024

Key opinion leaders analyze the implications of the FDA's accelerated approval for lisocabtagene maraleucel (liso-cel) in chronic lymphocytic leukemia, based on promising results from the TRANSCEND CLL 004 trial.

August 15, 2024

A medical expert offers commentary on the recent FDA accelerated approval of pirtobrutinib, discussing the implications of the BRUIN trial findings that supported this decision for chronic lymphocytic leukemia treatment.

August 14, 2024

ASCO has released a research statement outlining 4 recommendations to decentralize clinical trials and improve patient access to these studies.

August 08, 2024

Tanios Bekaii-Saab, MD, FACP, discusses final results from the MOUNTAINEER trial in HER2+ metastatic colorectal cancer.

August 07, 2024

Kashul Parikh, MBBS, discusses research efforts dedicated to leveraging antibody-drug conjugates with varying targets in lung cancer.

August 07, 2024

Tanios Bekaii-Saab, MD, FACP, discusses the benefits of multidisciplinary conferences within the gastrointestinal cancer treatment field.

August 05, 2024

Kaushal Parikh, MBBS, highlights how PD-L1 expression affects treatment decision-making in the absence of other targetable mutations or prognostic indicators in non–small cell lung cancer.

August 02, 2024

Kaushal Parikh, MBBS, discusses treatment advances in early-stage NSCLC including for patients with actionable mutations, and details considerations with adjuvant approaches.

August 02, 2024

Researchers at the Mayo Clinic found that patients with BCP-ALL who lacked the Philadelphia chromosome and were in remission showed higher survival rates with blinatumomab plus chemotherapy.

July 31, 2024

Eileen M. O’Reilly, MD, and Tanios S. Bekaii-Saab, MD, FACP, discuss key topics in gastrointestinal cancer to be presented during the 2024 ISGIO Meeting.